![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/10/2019 17:09 | I hope not (loan) | ![]() bermudashorts | |
11/10/2019 16:32 | Waterloo01 A loan would be the answer provided it was unsecured but they are clearly working on something but not much time left. | ![]() chrisatrdg | |
11/10/2019 15:20 | Chris, there is a limit to how much Mr Dungan can put in without taking full ownership. He has deep enough pockets. Shame when he approached them they didn't ask for twice as much. Can't all come from grants, as even Barda have said they can't carry all the weight, so guess they are hoping the antibiotic environment improves over the next few months (disarm act?) and either Mr D brings someone else in or someone makes them an offer. Need a change in environment for that. I can see they are doing their best and if this were almost any drug bar an antibiotic, it would be hugely valuable. Maybe we should be hoping for some sort of antibiotic Apocalypse, although I'm not sure I value my investment that much! Edit: Mr D however might be able to stand behind a loan of some description? I await some better insight. | ![]() waterloo01 | |
11/10/2019 15:13 | Can anyone post a link to conference call | ![]() kirk 6 | |
11/10/2019 13:11 | High waterloo01 I will also be listening to the calls when one can learn a lot.Not surprised no movement on cash run way but you do not take on staff as announced today if you are not confident of being able to get some form of funding soon.I cannot see they can go much longer without making some form of announcement as from now they only have a few months left so they must come up with something by 31st December.Hey ho. Edit: Based on what I am hearing considering how much Summit needs next year & yet we are so close to the 'cliff edge' clearly they are going for broke with their 'foot hot on the metal' in order to move the project.I can only conclude that they have a fall back position. Edit Edit: Glyn referred to shareholders & that its not done till its done maybe Summit are going for a float requiring major shareholders to dip further into their pockets & accept heavy dilution & at a premium. Any thoughts anyone? | ![]() chrisatrdg | |
11/10/2019 12:14 | End Jan 2020. Was hoping they might have announced funding alongside. Sure it will come up on the call. | ![]() waterloo01 | |
11/10/2019 11:48 | Lets see what they say about cash runway | ![]() waterloo01 | |
11/10/2019 11:06 | Just been looking back for any recent research notes on SUMM. In the UK the last on was from N+1 Singer on 07/June/2019. Hopefully they'll issue an update after today's results and reflecting recent good news. N+1 Singer 07 June 2019 Summary: "Direct US sales strategy drives valuation upgrade We have updated forecasts to reflect Summit's plan to establish a direct sales team in the US for ridinilazole, currently in Phase III for the treatment of C. difficile infection (CDI). As a result, our intrinsic value estimate is upgraded to 66p/share (from 48p), with Summit's growing portfolio of preclinical, new-mechanism antibiotics providing potentially substantial further upside. We reiterate our positive stance..." | ![]() someuwin | |
11/10/2019 10:12 | Agreed great to hear haven't had the chance to listen to it fully. Never expect much from results but will probably make an interesting read with all the recent positive news | ![]() kirk 6 | |
11/10/2019 09:50 | Hi freedosh I am so glad you have said that & good to hear you again.For me it was the best presentation by Summit I have ever followed.Summit have a really strong team they now just need the money to take them beyond March 2020. Todays results & related feed back from the finance media will be interesting. Regards to all. | ![]() chrisatrdg | |
11/10/2019 09:31 | Good to hear freedosh. | ![]() someuwin | |
10/10/2019 19:48 | Just listened to the first 1:53hrs Brilliant, absolutely brilliant. Well done all at Summit. | ![]() freedosh | |
10/10/2019 17:19 | Results tomorrow | ![]() kirk 6 | |
10/10/2019 17:08 | Link to this weeks US presentation: | ![]() chrisatrdg | |
09/10/2019 19:57 | Thanks Chris I reckon uk will catch up before week is out | ![]() kirk 6 | |
09/10/2019 12:53 | Hi kirk6 You are spot on all a bit of a mystery. | ![]() chrisatrdg | |
08/10/2019 21:17 | Closed 1.85 or 30p equivalent if I'm right in the conversion | ![]() kirk 6 | |
07/10/2019 20:11 | At the end of the conference financials were mentioned & Glyn said in the next week / ten days or to that effect but certainly by the end of next week.It will be interesting to read the notes re 'Going Concern' in relation to when its cash run way ends. | ![]() chrisatrdg | |
07/10/2019 19:57 | Bermuda, kind of old news as they have been suggesting that in most of the presentations in the last few month, 1st and 2nd line. They have designed the trial to include the economic benefits, but your right, it's not be 'expressed' so clearly before. It is central to their whole approach these days. Superiority and strong economic case. As we know, too many antibiotic companies have foundered on not approaching those two issues (let alone safety). Me too doesn't wash through the $$ model. | ![]() waterloo01 | |
07/10/2019 19:52 | Waterloo - not sure I have researched here as much as I should have but the comment re. labelling for Rid. was interesting - ie. they believe they can secure a much wider label than competitors to include not just the treatment of CDI but also reducing the recurrence. Is this old news? If so I've missed it. | ![]() bermudashorts | |
07/10/2019 19:38 | Pipeline was in the last part concerning Discuva etc & it was a very good presentation. | ![]() chrisatrdg | |
07/10/2019 19:20 | I missed quite a lot but the hour I listened into makes a very compelling case for RDZ as front line treatment. They do look to have learnt the lesson of having endpoints that include the economic model. Very convincing team. Potential big prize if..... Did they bring up the rest of the pipeline in the first part? | ![]() waterloo01 | |
07/10/2019 17:02 | Will listen to that later thanks Can't believe this hasn't gone up much more | ![]() kirk 6 | |
07/10/2019 15:12 | Todays presentation, which I am still listening to, is ground breaking Summit with its new additions to its marketing team.Summit are aiming for great highs. Edit: Best presention ever !!!!!! | ![]() chrisatrdg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions